Pharmaceuticals announced that the Journal of Prevention of Alzheimer’s Disease published the results of the Phase 1 INTERCEPT-AD clinical trial demonstrating that sabirnetug was generally ...
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) ...
HSV-1 is a common virus. During infection, its DNA incorporates into host chromosomes, where it lies dormant. An estimated two-thirds of adults worldwide carry these latent HSV-1 genes. Previous work ...
Despite a more widespread shift toward product recyclability, these types of linear systems are still especially prevalent in the plastics industry. Typical product life cycles range from short-lived, ...
The dengue virus (DENV) is a single-stranded RNA virus with increasing worldwide prevalence causing severe mosquito-borne viral infections. Therefore, effective strategies to prevent and treat DENV ...
Polyimides may be thermoplastic, with a high melt viscosity requiring high pressure to form molded parts. Polyimides may also be thermosetting, whereby imide oligomers are crosslinked into a ...
Image: Adobe Stock GAL-101 targets misfolded A monomers to prevent the formation of toxic A oligomers and protofibrils. The drug is currently being developed for both oral and topical formulations ...
"We knew that these condensates are often initiated by a single viral protein capable of binding genetic material, having a flexible region and forming oligomers, molecules made of small numbers ...